Together, our findings suggest that clinically available PDE4 inhibitors could be repurposed for CHCHD10<sup>S59L</sup>-linked ALS-FTD, while emphasizing the need to carefully consider the effects of the PINK1/Parkin pathway, as it is generally recognized as a protective pathway. This evidence concerns the gene PINK1 and amyotrophic lateral sclerosis.